Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics (Nasdaq: CNTX) granted a non-qualified stock option to purchase 146,000 shares of common stock to a new employee as an employment inducement under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Context Therapeutics (Nasdaq: CNTX) granted a non-qualified stock option to purchase 146,000 shares of common stock to a new employee as an employment inducement under Nasdaq Listing Rule 5635(c)(4). The award was granted outside the company’s 2021 Long-Term Performance Incentive Plan.

According to Context Therapeutics, the option was granted on the employee’s hire date, July 7, 2026, with an exercise price of $0.70 per share, equal to the Nasdaq closing price on the grant date. The stock option has a 10-year term and vests over four years: one-fourth on the first anniversary of the grant date and the remaining shares in 36 equal monthly installments, subject to continued service.

Argus Jul 13 session 4 alerts

-4.46% close to close 0.7x rel. volume Open Argus

Details

Market move: CNTX -4.46% in the Jul 13 session. inducement stock option grant

-9.0% Trough Tracked

$54.62M Mkt Cap at Peak Alert

On Jul 13, the first trading day after this news, CNTX closed 4.46% below the previous close. Argus tracked a trough of -9.0% from its starting point during tracking. Our momentum scanner recorded 4 alerts for this stock that day.

Data tracked by StockTitan Argus for the Jul 13 session.

Key Figures

Inducement option size: 146,000 shares Exercise price: $0.70 per share Option term: 10 years +5 more

Inducement option size

146,000 shares

Non-qualified stock option grant to new employee

Exercise price

$0.70 per share

Equal to CNTX Nasdaq closing price on July 7, 2026 grant date

Option term

10 years

Duration of inducement stock option

Initial vesting

25% after 1 year

One-fourth of shares vest on first anniversary of grant date

Subsequent vesting schedule

36 monthly installments

Remaining shares vest over next three years

Hire date

July 7, 2026

Grant date for inducement stock option

Nasdaq rule reference

Rule 5635(c)(4)

Basis for granting inducement option outside 2021 plan

Pre-headline price vs 52-week high

-83.58%

CNTX trading well below 52-week high before this announcement

Historical Context

5 past events · Latest: Jul 06

5 events

1. Jul 06

   Index inclusion

   24h Move

   +9.8%

   Added to Russell 2000 and 3000 equity indexes, boosting visibility.

2. Jun 15

   Clinical trial update

   24h Move

   -51.5%

   Positive interim Phase 1 CTIM-76 efficacy and safety data in PROC.

3. Jun 09

   Inducement option grant

   24h Move

   -4.6%

   Granted 146,000-share Nasdaq Rule 5635(c)(4) inducement option.

4. May 27

   Conference participation

   24h Move

   +13.3%

   Jefferies conference presentation plus 146,000-share inducement option grant.

5. May 18

   License amendment

   24h Move

   -0.5%

   Amended BioAtla CT-202 deal to fully paid-up, royalty-free economics.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock option, nasdaq listing rule 5635(c)(4), exercise price, vesting

4 terms

non-qualified stock option financial

"Context has granted a non-qualified stock option award to purchase 146,000 shares"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

nasdaq listing rule 5635(c)(4) regulatory

"was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"with an exercise price equal to the closing price of Context’s common stock"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"vest over four years, with one-fourth of the shares underlying the stock option vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PHILADELPHIA, July 10, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted a non-qualified stock option award to purchase 146,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context.

The stock option award was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted to a new employee on their hire date (July 7, 2026) with an exercise price equal to the closing price of Context’s common stock as reported by Nasdaq on the grant date ($0.70 per share).

The stock options have a 10-year term and vest over four years, with one-fourth of the shares underlying the stock option vesting on the first anniversary of the grant date and the remainder vesting in thirty-six equal monthly installments thereafter. Vesting of the stock options is subject to continued service with Context through the applicable vesting date.

About Context Therapeutics^®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context’s goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.

Investor Relations Contact:
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics
IR@contexttherapeutics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Context Therapeutics (CNTX) announce on July 10, 2026 about an inducement stock option grant?

Context Therapeutics announced a non-qualified stock option grant to a new employee for 146,000 common shares as an employment inducement. According to Context Therapeutics, the grant complies with Nasdaq Listing Rule 5635(c)(4) and was issued outside the company’s 2021 Long-Term Performance Incentive Plan.

How many shares are covered by Context Therapeutics’ July 2026 inducement stock option and at what exercise price?

The inducement stock option covers 146,000 shares at an exercise price of $0.70 per share. According to Context Therapeutics, the exercise price equals the closing price of CNTX common stock on Nasdaq on the July 7, 2026 grant date.

What is the vesting schedule for Context Therapeutics’ July 7, 2026 inducement stock option grant (CNTX)?

The stock option vests over four years, with one-fourth vesting on the first anniversary and the rest monthly. According to Context Therapeutics, the remaining shares vest in 36 equal monthly installments, contingent on the employee’s continued service through each vesting date.

Why was Context Therapeutics’ July 2026 stock option grant made outside the 2021 Long-Term Performance Incentive Plan?

The option was granted as an inducement award under Nasdaq Listing Rule 5635(c)(4), which allows grants outside shareholder-approved plans. According to Context Therapeutics, this structure supports hiring by offering equity incentives specifically tied to accepting employment with the company.

What is the term of Context Therapeutics’ inducement stock option granted on July 7, 2026 to a new CNTX employee?

The inducement stock option has a 10-year term from the grant date of July 7, 2026. According to Context Therapeutics, the option remains exercisable during this period, subject to standard conditions and the employee’s continued service for vesting.

How might Context Therapeutics’ 146,000-share inducement option grant affect CNTX shareholders?

The grant could modestly increase potential share count if fully exercised, slightly diluting existing holdings. According to Context Therapeutics, it represents a non-qualified option award to one new employee, intended as an inducement to join and remain with the company.